title: [Mucosal protective drugs].
abstract: New therapeutic strategy has been established for the management of acid-related diseases, GERD and peptic ulcer. The use of proton pump inhibitor is a first-line treatment for GERD. The therapeutic strategy for peptic ulcer is determined by the major causes, H. pylori infection and NSAIDs use. However, the use of alginate-raft formulations is a well-established treatment for heartburn and other symptoms related to GERD. Regarding H. pylori related gastric ulcer, some mucosal protective drugs have accelerated ulcer healing after H. pylori eradication treatment, which were demonstrated by two randomized, placebo-controlled double-blind trials conducted in Japan. Misoprostol and other mucosal protective drugs have a preventive effect against NSAIDs-induced gastric ulcer and are promising in NSAIDs user with low risks for gastrointestinal bleeding.
authors.forename: Toshiro
authors.initials: T
authors.lastname: Sugiyama
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D005764:Gastroesophageal Reflux / Q000188:drug therapy / Q000209:etiology; D016481:Helicobacter Infections / Q000150:complications; D016480:Helicobacter pylori; D006801:Humans; D009092:Mucous Membrane / Q000187:drug effects*; D020011:Protective Agents / Q000494:pharmacology*; D013276:Stomach Ulcer
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D020011:Protective Agents